Chimigen® Technology Platform
Akshaya's proprietary Chimigen® Platform is a unique, versatile and highly adaptable platform which can be used for developing immunotherapeutic agents and for cell-specific targeted delivery of biologicals including siRNA. Akshaya utilizes the Chimigen® Platform to develop therapeutic vaccines for patients with chronic viral infections as well as prophylactic vaccines to prevent infections.
The Chimigen® Platform is a flexible platform vaccine technology designed to elicit both humoral and cellular immune responses in hosts. Chimigen® Vaccines are recombinant proteins that have selected antigens fused to the Fc fragment of a murine monoclonal antibody through proprietary peptide linkers. Chimigen® Vaccines contain two domains, the Target Binding Domain (TBD) and the Immune Response Domain (IRD). This approach allows for efficient substitution of a desired antigen (the IRD) onto the TBD backbone, permitting production of highly desirable and effective multivalent vaccines.
Chimigen® Recombinant Molecule: A schematic diagram
The antibody (TBD) portion of the fusion protein allows the recombinant molecule to bind to specific receptors on the cell surface of dendritic cells (DCs) and other antigen presenting cells, facilitating antigen uptake, processing, presentation and thus inducing both cellular (T cell) and humoral (B cell, antibody) immune responses against the selected antigen(s). Induction of a broad and balanced immune response allows the technology to be used to develop both prophylactic and therapeutic vaccines and is a key advantage of the Chimigen® Technology. The generation of a strong and balanced Th1/Th2 immune response is critical for the elimination of virus-infected as well as cancer cells.
Chimigen® Technology Platform: download the powerpoint presentation